Gekko, thank you for sharing your perspective, which raises valid concerns about the company's history and current standing.
Indeed, a track record of lengthy time-to-market, limited sales, and shareholder value erosion could unsettle any investor. You're right; past performance has been far from rewarding, and the lack of communication or apparent progress can be upsetting.
However, it's also worth considering that the biotech sector is inherently high-risk and long-term, often requiring many years of R&D, regulatory approvals, and clinical trials before a company can generate sustainable revenue.
Furthermore, gaining approval from a body like the GBA for clinical trials could signify a turning point, marking the company's transition from a research-focused to a commercial stage.
It's essential to be cautious, and your concerns are a critical part of the broader investment discussion. However, for those who believe in the company's technology and its potential impact on patient care, such turning points could offer a new opportunity, despite the checkered past.
As always, due diligence and risk assessment are key when considering any investment.
- Forums
- ASX - By Stock
- OSL
- Ann: Entitlement Offer to raise up to $9.9 million
Ann: Entitlement Offer to raise up to $9.9 million, page-162
Featured News
Add OSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $13.32M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.4¢ | $23.68K | 4.971M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
29 | 23118264 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 5200224 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 20618264 | 0.004 |
8 | 4673547 | 0.003 |
6 | 5457516 | 0.002 |
4 | 7800000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 5200224 | 7 |
0.006 | 20507648 | 25 |
0.007 | 24737500 | 19 |
0.008 | 9543848 | 10 |
0.009 | 12462253 | 5 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online